AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 23, 2022 | Series B | $18M | 1 |
Morningside Venture Investments
|
— | Detail |
| Dec 23, 2021 | Grant | $2.10M | 1 |
NSW Health
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Morningside Venture Investments
|
Yes | Series B |
NSW Health
|
Yes | Grant |